Paper Details

  1. Home
  2. Paper Details

<i>In Vivo</i> Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum-&#946;-Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model.

Author: AbdelraoufKamilia, NicolauDavid P, StaintonSean M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the pharmacodynamics of ceftibuten-clavulanate (CTB-CLA) against ESBL-producing Enterobacteriaceae in a murine thigh infection model. The results suggest a susceptibility breakpoint of 4 mg/liter for CTB-CLA and support its consideration for the treatment of urinary tract infections due to ESBL-producing organisms.
Paper Details　
Original Abstract of the Article :
Ceftibuten-clavulanate (CTB-CLA) is a novel &#946;-lactam-&#946;-lactamase combination with potential utility for the management of urinary tract infections caused by extended-spectrum-&#946;-lactamase (ESBL)-producing organisms. We examined the pharmacodynamics of the combination against 25 <i>Ente...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591625/

データ提供：米国国立医学図書館（NLM）

Ceftibuten-Clavulanate: A Promising Combination for Treating ESBL-Producing Infections

Infections caused by extended-spectrum-β-lactamase (ESBL)-producing bacteria pose a significant challenge to healthcare. This research explores the pharmacodynamics of a novel β-lactam-β-lactamase combination, ceftibuten-clavulanate (CTB-CLA), in the treatment of ESBL-producing *Enterobacteriaceae* infections. The study examines the effectiveness of this combination against various ESBL-producing bacterial strains in a murine thigh infection model.

Combating ESBL-Producing Infections: A New Strategy with Ceftibuten-Clavulanate

The study demonstrates that CTB-CLA exhibits potent activity against ESBL-producing *Enterobacteriaceae*, suggesting its potential for treating urinary tract infections caused by these resistant organisms. The research further identifies the optimal dose and exposure parameters for CTB-CLA, providing valuable insights for clinical application. Imagine CTB-CLA as a team of camels, each carrying a specific weapon to combat the ESBL-producing bacteria, effectively dismantling their resistance mechanisms and restoring balance to the battlefield.

A New Weapon in the Fight Against Resistant Infections: Ceftibuten-Clavulanate

The study's findings provide a glimmer of hope in the battle against antibiotic-resistant infections. CTB-CLA could potentially become a valuable treatment option for ESBL-producing infections, offering clinicians a new tool to combat these challenging pathogens and improve patient outcomes.

Dr.Camel's Conclusion

This research highlights the potential of ceftibuten-clavulanate as a promising new therapeutic agent for treating infections caused by ESBL-producing bacteria. This study is a testament to the ongoing quest for new antibiotics, a journey that resembles a long caravan trek across the desert, seeking new strategies to combat ever-evolving threats.

Date :
  1. Date Completed 2020-05-18
  2. Date Revised 2020-05-18
Further Info :

Pubmed ID

31061165

DOI: Digital Object Identifier

PMC6591625

Related Literature

Article Analysis
・Effects of ceftibuten
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.